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Abstract 
Due to the highly restricted species-tropism of Hepatitis C virus (HCV) a limited number of animal models 
exist for pre-clinical evaluation of vaccines and antiviral compounds. The human-liver chimeric mouse 
model allows heterologous challenge with clinically relevant strains derived from patients. However, to 
date, the transmission and longitudinal evolution of founder viral populations in this model have not 
been characterized in-depth using state-of-the-art sequencing technologies. Focusing on NS3 protease 
encoding region of the viral genome, mutant spectra in a donor inoculum and individual recipient mice 
were determined via Illumina sequencing and compared, to determine the effects of transmission on 
founder viral population complexity. In all transmissions, a genetic bottleneck was observed, although 
diverse viral populations were transmitted in each case. A low frequency cloud of mutations (<1%) was 
detectable in the donor inoculum and recipient mice, with single nucleotide variants (SNVs) >1% 
restricted to a subset of nucleotides. The population of SNVs >1% was reduced upon transmission while 
the low frequency SNV cloud remained stable. Fixation of multiple identical synonymous substitutions 
was apparent in independent transmissions, and no evidence for reversion of T-cell epitopes was 
observed. In addition, susceptibility of founder populations to antiviral therapy was assessed. Animals 
were treated with protease inhibitor (PI) monotherapy to track resistance associated substitution (RAS) 
emergence. Longitudinal analyses revealed a decline in population diversity under therapy, with no 
detectable RAS >1% prior to therapy commencement. Despite inoculation from a common source and 
identical therapeutic regimens, unique RAS emergence profiles were identified in different hosts prior to 
and during therapeutic failure, with complex mutational signatures at protease residues 155, 156 and 
168 detected. Together these analyses track viral population complexity at high-resolution in the human-
liver chimeric mouse model post-transmission and under therapeutic intervention, revealing novel 
insights into the evolutionary processes which shape viral protease population composition at various 
critical stages of the viral life-cycle. 
Keywords 
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1. Introduction 
Direct Acting antivirals (DAAs) have revolutionized treatment of chronic HCV infection (Lange et al., 
2014; Polenakovik, 2015; Zhang et al., 2016). In 2003 the first anti-HCV DAA was described (BILN 2061, 
also known as Ciluprevir), providing proof of concept that targeting the HCV protease represents a 
potent therapeutic option (Lamarre et al., 2003). The non-structural protein 3 (NS3) is a multifunctional 
protein that contains a serine protease domain at its N-terminus. Inhibition of the NS3 protease supports 
viral clearance via both inhibition of viral polyprotein cleavage, reducing viral replication, in addition to 
restoration of MAVS and TRIF mediated innate immune signaling (Meylan et al., 2005). IFN-free DAA 
combination therapies including second generation NS3 PIs can achieve high clearance rates in hard-to-
treat patient groups (Buti et al., 2016; Zeuzem et al., 2015). However, despite the NS3 protease domain’s 
importance as a therapeutic target, genetic variability in viral NS3 protease populations remains poorly 
characterized in HCV infection at different stages of the viral life-cycle.  
 
Studying HCV transmission in a natural setting is challenging due to the often asymptomatic nature of 
infection (Irving and Brown, 2010), with limited numbers of studies characterizing samples from both 
donor and recipient(s). To circumvent the low availability of samples from donor/recipient pairs, 
permissive animal models can be used to model such scenarios (Vercauteren et al., 2015b), yielding 
novel insights into the transmission process (Brown et al 2012). HCV replication in infected hepatocytes 
is characterized by a high rate of virus production and a correspondingly high level of genetic diversity in 
circulating viruses (Simmonds, 2004; Tarr et al., 2015). This is due to the lack of efficient proofreading by 
the HCV RNA-dependent RNA polymerase. As a result, HCV exists as a dynamic swarm of genetically 
related genomes within infected patients rather than a clonal population (Martell et al., 1992; Pawlotsky, 
2006). While chimpanzees are permissive to infection with non-laboratory strains of HCV (Bukh, 2012) 
ethical concerns have resulted in research animals being retired in both the US and the EU. 
Consequently, the current state-of-the-art animal model for heterologous challenge with clinically 
relevant strains is the human-liver chimeric mouse model: the liver of Alb-uPA transgenic SCID mice can 
be engrafted with human adult hepatocytes rendering them permissive to HCV infection (Vercauteren et 
al., 2015b, 2014)  
 
In this study, we focused on the genomic region encoding the NS3 protease domain, tracking sequence 
evolution upon transmission to a new host and the subsequent susceptibility of newly transmitted viral 
populations to antiviral therapy. We modeled a single-source outbreak to multiple recipients, infecting 
multiple human-liver chimeric mice with a viral inoculum derived from a single chronically infected 
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patient. We utilized next generation sequencing (NGS) to track the evolution of viral protease 
populations upon viral transmission, comparing the donor viral population with founder populations in 
individual recipient mice. In addition, after transmission, we sought to track independent longitudinal 
evolution of NS3 protease populations under PI monotherapy in individual animals and the emergence of 
RAS at high-resolution.  
2. Material and Methods 
2.1. Experimental design  
Human liver-chimeric mice used  in this study were produced as previously reported (Meuleman et al., 
2005) and represent some of the monotherapy arm animals from Vercauteren et al. (2015). Mice were 
infected with a serum-derived virus (titer 2 × 105 IU/ml) from a chronically HCV infected patient 
(genotype 1b, P05) (Fafi-Kremer et al., 2010). Patient serum was obtained with informed consent 
following a protocol approved by the local Ethics Committee of the University of Strasbourg Hospitals 
(CPP 10-17). A high-titre viremia was established in the donor mouse (DM), which was subsequently 
utilized to infect eight recipient animals (r1-8: 1×10
4 
IU/mouse).  Virus was inoculated at least four weeks 
prior to start of Ciluprevir monotherapy, which was administered by oral gavage twice daily at 10 mg/kg. 
Ciluprevir is a peptidomimetic macrocyclic compound that binds non-covalently to the active site of the 
HCV NS3 serine protease. Viremia was tracked as previously described (Vercauteren et al. 2015).  
2.2. Viral population sampling 
RNA extraction, cDNA synthesis and amplicon generation were performed according to Vercauteren et 
al. (2015). Briefly, viral RNA was extracted from EDTA-plasma using a Viral RNA MiniElute kit (Qiagen). 
Synthesis of cDNA was achieved using 8 µl viral RNA, a genotype 1b specific primer and Superscript III 
reverse transcriptase (Invitrogen). Quantification of viral cDNA input into sequencing amplicons was 
determined via qPCR as previously described (Irving et al., 2014). Amplicon generation was performed 
via nested PCR using Platinum Taq High-fidelity polymerase (Invitrogen) and genotype 1b-specific 
primers. 
2.3. Illumina Miseq Sequencing 
NGS library preparation was performed in accordance with the manufacturer’s instructions using a 
TruSeq DNA PCR-Free Sample Preparation Kit (Illumina Inc., San Diego, CA, USA). Quality control of NGS 
libraries was performed using an Agilent Bioanalyzer HS Chip (Agilent Technologies). NGS library 
quantification was performed via qPCR (KAPA Library Quantification Kit) and 300 cycles of sequencing 
performed using a MiSeq Reagent Kit v3 (Illumina Inc.). 
2.4. Data Analysis: Read mapping and SNV calling 
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NGS data were analyzed as previously described (Irving et al., 2014; Vercauteren et al., 2015a) with 
minor modifications. The nucleotide consensus of the P05 NS3 protease population (540bp) was 
determined and used as a reference sequence in all subsequent assemblies. Raw Fastq files were 
mapped against the P05 consensus using CLC Genomics Workbench v8b (Qiagen Arhaus). BAM contigs 
were used to generate coverage plots and for SNV calling to track high-frequency SNVs (>1%): only SNVs 
exhibiting average PHRED scores >30 were included. To track ultra-low frequency SNVs (<1%) and 
estimate Shannon entropy in viral populations the reference-based short read aligner TANOTI (Vattipally. 
S) was used for mapping followed by a subsequent SNV calling employing DiversiTools (Hughes and 
Jortan) 
3. Results 
3.1. Characterization of viral population diversity pre and post transmission 
Comparative analyses of the viral population in the patient serum and donor mouse were performed to 
quantify any loss of population diversity, which may have occurred in the passaging process, and ensure 
a diverse inoculum was transmitted to recipient mice (Figure 1). Comparative analyses of protease 
populations in the DM and recipient animals were then performed by calculating Shannon Entropy. 
Shannon Entropy is a quantitative measure of uncertainty which can be used to determine the variability 
in a population of sequences. Sliding window analyses enabled visualization of cross-sectional diversity in 
viral populations and revealed diverse and distinct viral populations in the patient sera, DM and 
recipients (Figure 1). The majority of this population variability is low frequency although mutational 
hotspots indicating high levels of population heterogeneity are evident in most recipient animals. To 
ensure robust comparison of viral populations at different samplings, quantification of viral genomic 
input into sequencing amplicons was determined by qPCR (Irving et al., 2014). These comparisons 
revealed that viral population diversity was independent of genomic input. For example, population 
heterogeneity in patient P05 (6,840 genomes sampled) was greater than the DM (86,450 genomes 
sampled) despite shallower depth of genome sampling. These data also revealed viral populations take 
different evolutionary trajectories post-transmission: despite high-titer inoculation from a common 
source, some founder populations exhibit greater diversity (r1) while others appear genetically more 
homogenous (r8).  
3.2. Low frequency clouds of SNVs detected pre- and post-transmission 
The majority of detectable variation in NS3 viral populations was low frequency (Figure 2a). Cross-
sectional analyses of the patient serum (top panel) and recipient mice with either diverse (middle panel) 
or more homogeneous (bottom panel) viral populations revealed a low frequency (<1%) cloud of SNVs 
detectable across the entire sequence length. This cloud is maintained post-transmission in all recipient 
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animals. However, numbers of high-frequency SNVs (>1%) are reduced upon transmission and differ 
between individual recipient animals.  
3.3. High-frequency SNVs are differentially transmitted to recipient animals and reduced in number  
In the initial virus population of the patient, ~19% of sites (n=102) exhibited SNVs with >1% population 
frequencies. This was reduced ~12% of sites (n=64) in the DM and ranges between ~8% and ~3% in 
recipient animals (Figure 2b). The vast majority of high-frequency SNVs detected in all donor animals 
were transmitted (i.e. also detectable in the patient or donor inoculum at >1%). Very few high-frequency 
SNVs post-transmission were derived from the low-frequency SNV pool in the patient or donor inoculum, 
supporting the notion that restrictions exist on the mutational space that can be effectively explored by 
RNA virus populations (Brown et al., 2014). In all viral populations analyzed, an extreme 
transition/transversion bias existed, with the vast majority of high-frequency SNVs representing 
transitional mutations (C<>U or A<>G): this pattern was not altered post-transmission (Figure 2b). 
3.4. Synonymous mutations predominate post transmission and a subset becomes fixed  
Levels of synonymous (dS) and non-synonymous (dN) substitutions were determined pre- and post- 
transmission (Figure 3). Significant reductions in viral diversity were observed upon passage of the 
patient sera into the DM (p<0.001) and in each separate transmission of the DM to recipients (p<0.0001).  
In the patient serum, DM and recipient mice the consensus amino acid sequence remained identical. 
Although dN substitutions were detectable in 7/8 animals post-transmission, their population frequencies 
were low (<10%) and were restricted to 1-2 sites. No dN substitutions were detected at sites associated 
with DAA resistance or residues comprising the catalytic triad of the serine protease. Mapping against 
the P05 consensus enabled visualization of SNVs in the patient sera which were swept towards 
population fixation post-transmission. In 6/8 founder populations, nine dS SNVs exhibited evidence for an 
increase population frequency to become dominant (70-99% frequency: sites 21, 37, 99, 120, 312, 360, 
471, 480 and 519) (Figure 3).  
3.5. Susceptibility of founder populations to antiviral therapy  
Evolution of founder populations in response to antiviral therapy was tracked in five individual mice 
post-transmission (Figure 4). In all animals, viremia rapidly declined upon therapy initiation but quickly 
rebounded (Figure 4a). Absolute quantification of viral genomic input into sequencing amplicons 
revealed good sampling depth for all analyzed populations (Figure 4b). High frequency SNVs (>1%) were 
generally synonymous (Figure 4c) and transitional (figure 4d) in all animals with SNV >1% declining in 4/5 
animals over the course of therapy (Figure 4C & D). Despite this decline, an increase in both dN (Figure 
4c) and tv SNV frequencies (Figure 4d) was observed after therapy initiation.  
3.6. Population mutational signatures underlying RAS emergence 
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To visualize population diversity and RAS emergence at high-resolution, mouse r1 is shown as an 
example (Figure 5). Comparative analyses of viral populations over the course of therapy revealed a 
reduction in population diversity. After an initial increase, dS SNVs >1% declined after breakthrough. 
Prior to breakthrough, seven discrete RAS were detected at positions R155, A156 and D168 at different 
frequencies (Figure 5a). To illustrate population complexity observed at susceptible sites, mutational 
frequencies in the viral population underlying residue 168 are visualized in Figure 5b. These analyses 
reveal a homogenous population prior to therapy initiation followed by extreme population complexity 
prior to breakthrough. Underlying mutational complexity decreases post-breakthrough and again post 
therapy cessation, indicating complex population dynamics contribute to therapeutic failure which 
differs between hosts. 
3.7. Different profiles and trajectories of RAS emergence 
Patterns of RAS emergence differed between individual animals during monotherapy (Figure 6). In all 
animals, no RAS were detectable prior to therapy initiation. At viral nadir, complex RAS profiles were 
detectable in all animals, with transient RAS at residues R155, A156 (3/5 animals) and multiple 
simultaneous RAS at residue D168 (5/5 animals). RAS complexity decreased in all animals after virological 
breakthrough with RAS at R155 and A156 becoming undetectable. D168V RAS eventually became the 
dominant circulating variant in all animals. Together these data reveal that despite inoculation from a 
common source and identical therapeutic regimens, RAS emergence takes unique trajectories in 
different hosts prior to and during therapeutic failure. 
4. Discussion 
Previous studies which have tracked HCV transmission events from donor to recipient often focus on the 
envelope glycoproteins E1 and E2, which are located on the virion surface and represent the primary 
determinants of HCV entry (Tarr et al., 2015). These data indicate that, in specific instances, a genetic 
bottleneck is observed upon transmission due to initial infection with a limited number of founder 
viruses (D’Arienzo et al., 2013; Li et al., 2016, 2012; Wang et al., 2010). However, current antiviral 
therapies target the non-structural proteins and the effect of transmission on these important coding-
regions was previously poorly defined. To address this shortfall, we utilized NGS to track the effect of 
HCV transmission on NS3 protease populations in vivo. In some scenarios of HCV transmission, such as 
via needle stick injury or intravenous drug use, a limited number of founder strains initiate productive 
infection (D’Arienzo et al., 2013; Li et al., 2016, 2012; Wang et al., 2010). These scenarios are not 
accurately modeled in our study as a relatively high multiplicity of infection was used to inoculate 
recipient animals. However, in instances of vertical transmission from mother-to-child (Honegger et al., 
2013) or graft re-infection post orthotopic liver transplantation (Fafi-Kremer et al., 2010), a high 
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multiplicity of strains can potentially initiate infection. Our study is likely to recapitulate the viral 
population complexity transmitted in these scenarios. Furthermore, our analyses confirm that diverse 
viral populations, similar to those observed in natural infection, can be transmitted in animal challenge 
studies for studying preclinical effectiveness of vaccine candidates and novel therapeutic regimens. 
However, in addition to viral load, the diversity of transmitted populations differs between individual 
recipients and this should be monitored and taken into consideration when interpreting results. 
 
E1E2 evolution at transmission has been explored in multiple previous studies. Vertical transmission 
selects for E1E2 variants with increased replication fitness due of CTL escape mutations (Honegger et al., 
2013). Experimental infection of chimeric liver mice selects for E1E2 variants with increased capacity for 
cellular entry (Brown et al., 2012) while in orthotopic liver transplantation, preferential transmission of 
neutralization resistant E1E2s with enhanced entry capacity occurs (Fafi-Kremer et al., 2010; Felmlee et 
al., 2016; Fofana et al., 2012). In our study focusing on the HCV protease, no evidence for T-cell reversion 
was observed upon transmission. However, while no selection of advantageous amino acids was 
observed, multiple silent transitional substitutions, which were present at >1% in the initial patient 
serum or donor inoculum, became dominant in the population post-transmission. Whether these 
fixations confer a replication or translation advantage into viral populations in a new host liver remains 
untested and requires further investigation. However as an identical pattern was detected in 
independent transmissions, this observation is unlikely due to random genetic drift. Despite high-titer 
inoculations, sites exhibiting variation >1% in the population were reduced in all recipients, with 
differential levels of viral diversity transmitted: most detectable variation was due to synonymous 
transitions. NS3 was surprisingly stable upon transmission, with an identical amino acid consensus in the 
donor and all recipients. These data indicate a combination of strong purifying selection and a genetic 
bottleneck shape viral protease evolution at transmission. The majority of nucleotide positions exhibit 
only low-frequency SNVs in the patient sera, DM and recipient animal, indicating that selective 
constraints limit the frequencies of SNVs that can reach high frequencies in the viral population. 
 
While single genome amplification (SGA) has advantages over clonal sequencing to assess viral 
population diversity (Salazar-Gonzalez et al., 2008), sampling depth remains highly restricted and 
represents only a fraction of the total population. NGS allows viral populations to be scanned at 
unprecedented depth, orders of magnitude greater than previous approaches. Our analyses reveal the 
presence of a low frequency mutational cloud in all populations analyzed. The extent and diversity of this 
cloud, or the extreme RAS heterogeneity observed prior to virological breakthrough would not be 
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accurately represented using clonal/SGA approaches. The virally encoded RdRp is responsible for 
genome replication via a negative stranded intermediate and has low fidelity. The resultant mutational 
spectrum generated facilitates the rapid emergence of escape mutants in response to selective 
pressures. Due to the limitations of current technologies, a proportion of the low frequency SNVs 
detected are likely to represent assay noise (Whitfield and Andino, 2016).  However, the low frequency 
SNV cloud observed also contains a combination of defective or fitness-impaired viral genomes and 
represents the raw variation on which natural selection can act in viral populations, evidenced by the 
rapid emergence of RAS upon therapy initiation. In conclusion, these analyses provide novel insights into 
the dynamics of HCV protease populations at transmission and under therapeutic intervention, 
quantifying the evolutionary processes shaping NS3 sequence divergence and governing RAS emergence 
in vivo. 
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Figure Legends 
Figure 1: The effects of transmission on HCV population diversity. Cross-sectional viral diversity in the 
genomic region encoding the NS3 protease domain in patient serum (top panel, black), donor inoculum 
(second panel, black) and eight recipient human-liver chimeric mice (bottom panels, grey). The x-axis 
represents the 540 nucleotides encoding the N-terminus of NS3, while the y-axis represents diversity in 
the viral population measured in Shannon entropy. Sample identifiers are presented to the right of 
individual plots. Numbers within individual plots represent the genomic input into respective sequencing 
amplicons and were determined via 5’UTR RT-qPCR (Irving et al., 2014). 
 
Figure 2: SNV frequencies pre- and post-transmission. (A) Cross-sectional detection of a low-frequency 
mutational cloud in the patient serum (upper panel) and two example recipient mice (lower panels).  The 
x-axis represents the 540 nucleotides encoding the N-terminus of NS3, while the y-axis represents the 
depth of nucleotide coverage across this region. Sample identifiers are presented in the top right of 
individual plots. The thick black line represents total nucleotide coverage at a specific position whilst the 
frequencies of individual nucleotides are color-coded. Population frequencies above 1% are highlighted 
in light-grey while frequencies below 1% are highlighted in dark-grey. (B) Proportions of low- and -high 
frequency transmitted SNVs. Pie charts represent total nucleotides analyzed per sample (540bp). For all 
samples, SNVs exhibiting variation <1% (low-frequency) are highlighted in white. For the patient sera, the 
total SNVs exhibiting variation >1% (high-frequency) are highlighted in pink. To visualize whether there 
was a preference for transmission of high-frequency SNVs, for the donor inoculum and individual 
recipient mice, SNV >1% which were also detected in the patient inoculum at >1% are highlighted in 
grey.  SNVs present at >1% in recipient mice that remained either undetected or had frequencies <1% in 
the patient serum are highlighted in black. To the left of each pie chart, high-frequency SNVs are 
categorized in bar charts for each sample, with different transitional substitutions highlighted in shades 
of blue and transversions highlighted in yellow.  
 
Figure 3: Synonymous and non-synonymous SNV frequencies pre- and post-transmission: Cross-
sectional quantification of silent and amino acid changing SNVs in the NS3 protease domain in patient 
serum (top panel, white background), donor inoculum (second panel, white background) and eight 
recipient human-liver mice (bottom panels, grey background). For each plot, all mutations present at 
greater than 1% are plotted relative to the P05 consensus master sequence. The x-axis represents the 
180 codons of the NS3 protease domain. The y-axis represents the relative percentage frequencies of 
SNVs across the entire NS3 protease domain, with synonymous (dS, black bars) and non-synonymous (dN, 
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blue bars) frequencies in the viral population.  Sample identifiers are presented to the right of individual 
plots with the absolute number of sites exhibiting variation boxed below. Statistical significance was 
calculated via Yates corrected Chi
2
 tests, with adjusted p-values for multiple comparisons. SNVs which 
become dominant post transmission are marked with * 
Figure 4: Longitudinal evolution of the protease domain during PI monotherapy. (A) Each panel 
represents monotherapy duration in animals r1-r5, with days presented on the x-axis and viremia on the 
y-axis. Labelled open symbols represent samples which were available for NGS while the pink 
background indicates the duration of monotherapy. For all animals, A represents the pre-therapy 
sample, B represents the pre-breakthrough sample and C represents the post-breakthrough sample. For 
r1 and r4, an additional sample D was also available after cessation of monotherapy. (B) Viral genomic 
input into sequencing amplicons. (C) Quantification of total SNVs >1% (black line) and the proportions of 
synonymous (dS) (grey line) and non-synonymous (dN) (blue bars) SNVs in individual mice over the course 
of PI monotherapy. (D) Quantification of total SNVs >1% (black line) and the proportions of transitions 
(green line) and transversions (green bars). 
 
Figure 5: Progressive evolution of the entire protease domain and complex patterns of RAS emergence 
under PI monotherapy. (A) Substitutional evolution across the entire protease domain in mouse r1 pre, 
during and post-monotherapy.  For each plot, all mutations present at greater than 1% are plotted 
relative to the P05 consensus master sequence. Pre and post-therapy plots have grey backgrounds while 
on-therapy plots have pink backgrounds. The x-axis represents the 180 codons of the NS3 protease 
domain. The y-axis represents the relative percentage of SNVs across the entire NS3 protease domain, 
with dS (black bars), dN (blue bars) and RAS (red bars) in the viral population presented. (B) Example of 
complex mutational signatures underlying RAS emergence. Web-logos (Crooks et al., 2004) depicting the 
population frequencies of nucleotides at individual codon positions underlying amino acid residue 168 in 
mouse r1 are presented in chronological order, from left to right. 
 
Figure 6: Profiles of RAS emergence during PI monotherapy. Each panel represents RAS emergence in 
animals r1 to r5 over the course of monotherapy. Within each panel, individual RAS are plotted 
separately to enable visualization of distinct emergence trajectories.  Green lines represent RAS at R155, 
blue lines represent RAS at A156 and red lines representing RAS at D168, with individual RAS at these 
positions labeled. 
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Highlights 
• Single-source HCV outbreak modelled in vivo using chimeric human-liver mice and 
tracked via NGS 
• Genetic bottleneck and strong purifying selection shape viral populations at transmission  
• Founder populations evolve along different trajectories post transmission 
• Founder populations susceptible to antiviral monotherapy 
• Complex patterns of RAS emergence with unique signatures in individual mice 
 
